{"id":"W2605009867","doi":"10.1158/1078-0432.ccr-16-2818","title":"A Phase 2/3 Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Lenalidomide Versus Investigator's Choice in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma","year":2017,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":164,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"National Institutes of Health; American Association for Cancer Research","keywords":"Lenalidomide; Medicine; Internal medicine; Diffuse large B-cell lymphoma; Neutropenia; Clinical endpoint; Oncology; Rituximab; Thalidomide; Phases of clinical research; Febrile neutropenia; Gastroenterology; Surgery; Lymphoma; Multiple myeloma; Randomized controlled trial; Clinical trial; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003692753,0.002161064,0.003081039,0.0005073724,0.0006827628,0.001389781,0.001200324,0.002055671,0.005738318],"category_scores_gemma":[0.002467263,0.0009390438,0.001935911,0.0004773508,0.001845139,0.00154618,0.0004433763,0.004251711,0.001035602],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001391099,"about_ca_system_score_gemma":0.001986389,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008578795,"about_ca_topic_score_gemma":0.00209883,"domain_scores_codex":[0.9987803,0.0007537185,0.0000619601,0.0001877283,0.00007428068,0.0001420251],"domain_scores_gemma":[0.9981552,0.0004636105,0.0004293003,0.0001703921,0.0001187955,0.0006627542],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9687737,0.01797826,0.001002753,0.0002197727,0.0004900426,0.00003672553,0.0000527856,0.0002981569,0.003045905,0.00008722425,0.0006495765,0.007365223],"study_design_scores_gemma":[0.9349864,0.06312171,0.000853643,0.000008542655,0.000123342,0.0000211419,0.00001211854,0.0002868943,0.0002318274,0.00009351029,0.0002529948,0.000007886926],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9878091,0.00182887,0.0006528492,0.0007690653,0.0003940991,0.006037646,0.001053559,0.00009797703,0.001356781],"genre_scores_gemma":[0.9844322,0.0009955524,0.002245942,0.001803485,0.0005503754,0.006886568,0.001340183,0.0000354846,0.001710169],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005738318,"threshold_uncertainty_score":0.01952934,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2495991745781395,"score_gpt":0.5288692121540582,"score_spread":0.2792700375759187,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}